Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Charles H. Sherwood sold 63,799 shares of the stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the completion of the sale, the chief executive officer now directly owns 174,705 shares in the company, valued at $8,873,266.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Anika Therapeutics Inc. (NASDAQ ANIK) opened at 52.82 on Friday. The stock has a 50 day moving average price of $49.79 and a 200-day moving average price of $47.14. Anika Therapeutics Inc. has a 1-year low of $41.38 and a 1-year high of $53.99. The stock has a market capitalization of $774.24 million, a PE ratio of 23.47 and a beta of 1.69.
Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The firm had revenue of $33.50 million for the quarter, compared to the consensus estimate of $27.20 million. During the same period in the previous year, the business earned $0.57 EPS. The firm’s revenue for the quarter was up 25.9% on a year-over-year basis. On average, analysts forecast that Anika Therapeutics Inc. will post $2.20 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/19/anika-therapeutics-inc-anik-ceo-sells-3240351-21-in-stock-updated-updated.html.
A number of equities research analysts have recently commented on ANIK shares. Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 8th.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.